Humedix휴메딕스

Humedix's profits have held up well through 2026, but the share price has fallen about half over the past year.

Humedix, a Korean maker of hyaluronic acid-based aesthetic and medical products, reported trailing twelve-month revenue of ₩177.9B and net income of ₩45.9B to H1 2026, with a 22.9% operating margin and low leverage. The share price closed at ₩23,700 on 2026-10-23, roughly half its 52-week high, and trades at about 5.7 times earnings and 0.8 times book value. The data does not include analyst ratings or price targets, and a DCF model in the pack puts base-case fair value at ₩70,513.

What stands out

• Trailing revenue of ₩177.9B is up from ₩170.1B in 2025, but 2025 revenue growth of 5.1% was slower than the 23.6% and 31.5% gains seen in 2023 and 2022.
• Operating margin has eased from 26.7% in 2024 to 22.9% on a trailing basis, while net income is well above operating income, which the data does not explain.
• Liabilities are 8.6% of equity and no borrowings are reported, with cash of ₩46.7B and free cash flow of ₩25.9B.
• The filings show a share buyback trust, a share cancellation decision, and an interim dividend, and the pack lists a 3.9% dividend yield.
• China distribution news on 2026-10-23 covers an extended exclusive partnership for the Elravie filler, but the data gives no financial size for this deal.

What to watch

• The share price has fallen 52.7% over one year, and the data does not say why; the trend and any company response are worth tracking.
• Foreign ownership fell from 7.5% to 6.7% over 60 days, while foreign and institutional investors were net buyers and retail investors were net sellers over the last 20 days.
• Next scheduled results and filings are not listed in the data; the most recent half-year report came out on 2026-08-14.